Results 101 to 110 of about 27,707 (119)

GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes

Journal of the American College of Cardiology, 2023
John McMurray, João S. Neves
exaly  

Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine

International Journal of Molecular Sciences, 2021
Hideaki Kaneto, Hideaki Kaneto, Masashi Shimoda   +2 more
exaly  

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes

Journal of Clinical Medicine, 2021
Eusebio Chiefari, Antonio Brunetti, Antonio Aversa   +2 more
exaly  

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Lancet, The, 2021
Shizuka Kaneko, Julio Rosenstock, Juan Frias   +2 more
exaly  

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

Frontiers in Endocrinology, 2022
Baptist Gallwitz
exaly  

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Cell Metabolism, 2017
Christophe Schmitt, Matthias Tschöp, Richard DiMarchi   +2 more
exaly  

Albiglutide: A New GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes

Annals of Pharmacotherapy, 2014
Wesley Nuffer
exaly  

Dulaglutide: The Newest GLP-1 Receptor Agonist for the Management of Type 2 Diabetes

Annals of Pharmacotherapy, 2015
Angela M Thompson
exaly  

Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes

Postgraduate Medicine, 2014
Laura Fernández Landó, Leonardo Mancillas-Adame   +1 more
exaly  

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Lancet, The, 2018
Deborah A Robins, Shweta Urva, Michael A. Nauck   +2 more
exaly